ストックスクリーナーアプリを入手
0.4422
2.12%
0.0092
アフターアワーズ：
.44
-0.0022
-0.50%
Verrica Pharmaceuticals Inc (VRCA) 最新ニュース
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Exclusive: Verrica Pharmaceuticals CEO Fireside Chat at Major Healthcare Conference - Stock Titan
Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer - MSN
Verrica Pharmaceuticals appoints new CMO to advance skin treatments By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer - GlobeNewswire
Verrica Pharmaceuticals appoints Rosenberg as CMO - MSN
Verrica Pharmaceuticals appoints new CMO to advance skin treatments - Investing.com
Dermatology Drug Pioneer Joins Verrica to Accelerate YCANTH Growth - Stock Titan
Verrica Pharmaceuticals Inc (VRCA)’s stock price range in the last year - US Post News
Verrica Pharmaceuticals Reports Positive Q4 2024 Results - TipRanks
Verrica Pharmaceuticals’ chief legal officer sells shares for $2,804 By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals’ chief legal officer sells shares for $2,804 - Investing.com
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates - MSN
Equities Analysts Offer Predictions for VRCA Q4 Earnings - Defense World
Verrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline Progress - MSN
Brookline Capital Management Comments on VRCA Q1 Earnings - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Earns “Hold” Rating from Needham & Company LLC - Defense World
GLP-1 Receptor Agonist Market Projected To Witness Substantial Growth, 2025-2032: Verrica Pharmaceuticals, - EIN News
Verrica Pharmaceuticals stock hits 52-week low at $0.57 By Investing.com - Investing.com Australia
Verrica Pharmaceuticals stock hits 52-week low at $0.57 - Investing.com India
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Verrica Pharmaceuticals beats EPS, misses revenue in Q4 2024 - Investing.com Australia
Strategic Growth and Market Positioning Drive Buy Rating for Verrica Pharmaceuticals - TipRanks
Verrica Pharma's Q4 Net Loss Narrows, Revenue Declines - Nasdaq
Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ... - Yahoo
Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlig - GuruFocus.com
Verrica Pharmaceuticals earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Verrica Pharmaceuticals beats EPS, misses revenue in Q4 2024 By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Verrica Pharmaceuticals reports Q4 EPS (24c), consensus (24c) - TipRanks
Verrica Pharmaceuticals Inc. SEC 10-K Report - TradingView
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Holdings Raised by Rhumbline Advisers - Defense World
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference - MyChesCo
Common Warts Clinical and Non-Clinical Studies, Key Companies, - openPR
Verrica Pharmaceuticals Announces Q4 & Full Year 2024 Financial Results Webcast - MyChesCo
Verrica Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 - The Manila Times
When Will Verrica Pharmaceuticals Release Its 2024 Financial Results? - StockTitan
Verrica Pharmaceuticals CEO to Speak at TD Cowen 45th Annual Health Care Conference - MSN
Verrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline Development - MSN
Verrica Pharmaceuticals stock hits 52-week low at $0.61 By Investing.com - Investing.com Canada
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):